Cat.#: BBM-C-183
Description | Human iPSC From Adipose Mesenchymal Stromal Cells from Ace Therapeutics are generated using an episomal reprogramming containing a proprietary mix of vectors, containing Oct-4, Sox-2, Klf-4 along with p53 Anti-sense, EBNA-1. The cell line was validated for pluripotency based on colony morphology, alkaline phosphatase expression, and expression of SSEA-4.iPS colonies exhibit classical morphology and growth. |
Species | Human |
Source | Adipose Mesenchymal Stromal |
Recommended Medium | It is recommended to use Human iPSC From Adipose Mesenchymal Stromal Cells Medium Kit for culturing in vitro. |
Cell Type | Induced Pluripotent Stem Cell |
Disease | Normal |
Quality Control | Human iPSC From Adipose Mesenchymal Stromal Cells test negative for bacteria, yeast, fungi, and mycoplasma. |
Shipping and Storage | Ace Therapeutics ships frozen cells using dry ice. Upon receiving the frozen cells, immediately move them into liquid nitrogen (-180 °C) for storage. Note: Never can cells be kept at -20 °C, and repeated freezing and thawing of cells is not recommended. |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Description | Price |
---|---|---|---|
BBM-C-180 | Human iPSC-derived Astrocytes |
Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.
|
inquiry |
BBM-C-178 | Human iPSC Line (Episomal, CB) |
The human iPSC line (episomal, CB) from Ace Therapeutics is a type of human induced pluripotent stem cell (iPSC) that was derived from human newborn cord blood (CB) mononuclear cells. The cells were reprogrammed into an embryonic-like pluripotent state using a method involving the introduction of OCT4, SOX2, KLF4, L-MYC, and Lin28 genes through episomal plasmids.
|
inquiry |
BBM-C-171 | Human Cord Blood CD34/CD133+ Progenitor Cells |
CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium.
The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells.
Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.
|
inquiry |
BBM-C-173 | Human Umbilical Cord Blood Mononuclear Cells |
Human Umbilical Cord Blood Mononuclear Cells are a mixture of various cell populations with a single nucleus, including hematopoietic and mesenchymal stem cells, endothelial progenitor cells, lymphocytes, and monocytes. They can be induced to differentiate into neuron cells, osteoblasts, and lymphocytes.
Human Umbilical Cord Blood Mononuclear Cells from Ace Therapeutics are isolated from umbilical cord blood. Cells are isolated by density gradient separation and cryopreserved immediately to ensure the best viability. Human Umbilical Cord Blood Mononuclear Cells are quality tested with less than 2% red blood cells.
|
inquiry |
BBM-C-174 | Human Bone Marrow CD133+ Stem/Progenitor Cells |
Human Bone Marrow CD133+ Stem/Progenitor Cells from Ace Therapeutics are isolated using positive immunomagnetic cell separation procedures from bone marrow.
Capable of a high level of proliferation and a wide range of differentiation, transplantation of bone marrow CD133+ cell lines has been shown to not only induced multilineage human hematopoiesis through the CD34+ lineage but also induce regeneration of cell lines in vitro in multiple locations by differentiating into endothelial cells, neural cells, hepatocytes, osteoblasts, and myocytes, with the list of tissue types this cell can differentiate into gradually increasing.
|
inquiry |
BBM-C-181 | Human Mesenchymal Stem Cells from Placenta (hPSCs) |
Human Mesenchymal Stem Cells from Placenta (hPSCs) from Ace Therapeutics are human mesenchymal stem cells (hMSC) isolated from placental tissue, specifically from amnion, decidua, or chorion villi. MSC have been shown to differentiate in vitro into adipocytes, chondrocytes, osteoblasts, myocytes, and β-pancreatic islets cells. They can also transdifferentiate into neuronal cells and hepatocytes.
|
inquiry |
BBM-C-167 | Human Embryonic Hematopoietic Stem Cell |
Human Embryonic Hematopoietic Stem Cells (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice.
Cells are only guaranteed with the purchase of Ace Therapeutics‘s Media and Ace Therapeutics‘s Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.
|
inquiry |
BBM-C-168 | Human CD34+ Hematopoietic Stem Cell |
Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types.
Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.
|
inquiry |
BBM-C-182 | Human Placental Derived Mesenchymal Stem Cell |
Human Placental Derived Mesenchymal Stem Cell are a well-characterized population of adult stem cells. These adult stem cells have a broad therapeutic potential due to their capability to renew and differentiate into various lineages of mature cells that produce fat, cartilage, bone, tendon, and muscle when cultured under specific permissive conditions. These cells are expanded in a Mesenchymal Stem Cell Medium and then cryopreserved at passage 2. The human placental MSC express typical mesenchymal cell surface markers, such as CD105, CD73, and CD90 and are negative for hematopoietic markers including CD34, CD45, and endothelial cell marker CD31.
|
inquiry |
BBM-C-176 | Reprogrammed Human iPSC Line |
Human reprogrammed iPSC Cells established from endothelial progenitor cells that derived from peripheral blood.
|
inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.